Novavax (NVAX) Inventory (2021 - 2026)

Novavax's Inventory history runs 6 years deep, the most recent figure standing at $11.5 million for Q1 2026.

• On a quarterly basis, Inventory rose 11.64% year-over-year to $11.5 million in Q1 2026; TTM through Mar 2026 was $11.5 million, a 11.64% increase from a year earlier, with the FY2025 full-year figure at $11.5 million, up 31.96% from the prior year.
• Inventory fell to $11.5 million in Q1 2026 per NVAX's latest filing, from $11.5 million in the prior quarter.
• Across five years, Inventory topped out at $256.3 million in Q2 2022 and bottomed at $8.6 million in Q3 2024.
• The 5-year median for Inventory is $15.8 million (2024), against an average of $44.1 million.
• Across the five-year window, Inventory jumped 313.47% in 2022 and plunged 90.84% in 2023, its largest moves.
• Year by year, Inventory stood at $36.7 million in 2022, then increased by 13.67% to $41.7 million in 2023, then tumbled by 79.02% to $8.7 million in 2024, then jumped by 31.96% to $11.5 million in 2025, then retreated by 0.75% to $11.5 million in 2026.
• Per Business Quant, the three latest NVAX Inventory figures stand at $11.5 million (Q1 2026), $11.5 million (Q4 2025), and $13.5 million (Q3 2025).